Drug Resistant Epilepsy
Conditions
Brief summary
This randomised trial is undertaken to assess whether MAD or LGIT is non-inferior to KD with regard to seizure control at twenty-four weeks among children with drug resistant epilepsy. The hypothesis of the study is that in 1 to 15-year-old children with drug resistant epilepsy, use of Modified Atkins Diet (MAD) or Low Glycemic Index Therapy (LGIT) as an add on to the ongoing anti-epileptic drugs would not be inferior to ketogenic diet by \>15% in terms of seizure reduction from baseline seizure frequency at 24 weeks. The primary outcome of the study is to determine the efficacy of MAD as compared to KD and LGIT as compared to KD for seizure reduction in drug resistant epilepsy following 24 weeks of dietary therapy in 1 to 15-year-old children on anti-epileptic drugs. The change in seizure frequency will be estimated as percentage change in seizure reduction at 24 weeks as compared to baseline.
Interventions
OTHERKetogenic Diet
The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. The patients in KD arm will be admitted to the hospital for initiation of diet.
OTHERMAD
The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. Following the run in period of 4 weeks, the patients will be randomized to the MAD or LGIT or KD arm. MAD will be initiated on out patient basis.
OTHERLGIT
The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. Following the run in period of 4 weeks, the patients will be randomized to the MAD or LGIT or KD arm. LGIT will be initiated on out patient basis.
Sponsors
All India Institute of Medical Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Years to 15 Years
Healthy volunteers
No
Inclusion criteria
1. Children aged 1-15 years with drug resistant epilepsy (Drug resistant epilepsy for the study will be defined as seizure frequency \>4 seizures per month, and treatment failure of ≥2 prescribed antiepileptic drugs). 2. Willing to come for regular follow up
Exclusion criteria
1. Surgically remediable cause for drug resistant epilepsy 2. Proven inborn error of metabolism except those in which KD is indicated (i.e., Pyruvate Carboxylase deficiency and GLUT-1 Deficiency) 3. Previously received KD, MAD or LGIT 4. Known case of 1. Chronic kidney disease 2. Chronic liver disease/ GI illness 3. Chronic heart disease (congenital and acquired) 4. Chronic respiratory illness
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage change in seizure frequency after 24 weeks of dietary therapy as compared to baseline, in the arm KD as compared to MAD and in the arm KD as compared to LGIT | Baseline and six months | Percentage change in seizure frequency will be estimated as mean number of weekly seizures over preceding 4 weeks after 24 weeks of dietary therapy divided by mean number of weekly seizures over preceding 4 weeks at the baseline. It will be calculated for each of the three arms (KD; MAD; LGIT) and KD will compared to MAD and LGIT individually as the primary outcome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients who achieve >50% seizure reduction from baseline at 24 weeks after diet initiation | Baseline and twenty-four weeks | Proportion of patients who achieve \>50% seizure reduction from baseline at 24 weeks after diet initiation |
| Estimate behavior change as measured by Childhood behavior checklist in each of three arms at baseline, 12 weeks and 24 weeks after dietary therapy | Baseline, twelve weeks, and twenty-four weeks | — |
| Estimate cognition change as assessed by Vineland Social Maturity Scale in each of three arms at baseline, 12 weeks and 24 weeks after dietary therapy | Baseline and twenty-four weeks | — |
| Percentage change in seizure frequency after 24 weeks of dietary therapy as compared to baseline, in the arm MAD as compared to LGIT | Baseline and twenty-four weeks | Percentage change in seizure frequency will be estimated as mean number of weekly seizures over preceding 4 weeks after 24 weeks of dietary therapy divided by mean number of weekly seizures over preceding 4 weeks at the baseline. Change in seizure frequency in MAD and LGIT arm will be compared |
| Evaluate change in serum levels of micronutrients by laboratory testing in each of three arms at baseline and six months after therapy | Baseline and twenty-four weeks | Micronutrients like copper, zinc, retinol and vitamin E would be compared |
| Evaluate omega3 polyunsaturated fatty acid levels and correlate it with change in seizure frequency | Baseline and twenty-four weeks | — |
| Evaluate GI adverse events (diarrhoea, constipation and vomiting) assessed by parental questionnaire in each of the three arms at baseline and six months after therapy | Baseline and twenty-four weeks | — |
Countries
India
Outcome results
None listed